-
Regeneron Pharmaceuticals Inc
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 5,400
-
Executives
- P. Roy Vagelos
- Leonard Schleifer
- Robert Landry
- Daniel Van Plew
- Neil Stahl
- Robert Terifay
- Joseph LaRosa
- Michael Aberman
- Peter Powchik
- George Yancopoulos
-
Company address
- 777 Old Saw Mill River Road
- Tarrytown, NY 10591
- United States of America
- 1-914-847-7000
-
Investor Relation Site
Link
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreements with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor; and with Decibel Therapeutics, Inc. to discover and develop therapeutics for hearing loss and tinnitus. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals Inc: Slide deck